Companies › Orca Biosystems
2 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Orca-T allogeneic stem cell and T-cell immunotherapy composed of purified hematopoietic stem and | – | Phase 3 | Acute Myeloid Leukemia; Leukemia, Myeloid, Acute | Apr 2027 |
| OrcaGraft (Orca-Q) engineered donor allograft for allogeneic hematopoietic cell transplantation | – | Phase 1 | Acute Myeloid Leukemia | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05316701 | Orca-T | Phase 3 | Acute Myeloid Leukemia | Oncology | Jul 2024 |
| NCT06551584 | Orca-T | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT04013685 | Orca-T | Phase 1 | Acute Myeloid Leukemia | Oncology | Apr 2027 |
| NCT07216443 | Orca-T | Phase 2 | Leukemia, Myeloid, Acute | Oncology | Nov 2027 |
| NCT03802695 | OrcaGraft (Orca-Q) | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
No annotated target.
–
Binhui Biopharmaceutical 3D Medicines (Sichuan) PharmaEssentia Buzzard Pharmaceuticals Cellvax Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.